Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
Status:
Withdrawn
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended dose for the combination of
dasatinib and bendamustine in chronic lymphocytic leukemia (CLL).